Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, July 8 at 2:00 PM EDT

Register Free →

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development

Active
Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

Agency

Department Of Health And Human Services → National Institutes Of HealthView Agency

NAICS

N/A

Place of Performance

Not specified

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health
Contacts1 person available
OfficeUS
Organization / Agency
Department Of Health And Human Services → National Institutes Of Health
View Agency Profile
Office AddressUS
Contacts
Blueprint Neurotherapeutics Team

Full Description

Show more

The NIH Blueprint for Neuroscience Research is interested in continuing to support the BluePrint Neurotherapeutics Network for Small Molecules (BPN-SM)- a program designed to help investigators advance promising small-molecule therapeutics toward clinical testing. The BPN-SM program supports drug discovery and development activities in investigators’ own laboratories while also providing access to NIH-supported subject matter experts and contract research organizations (CROs) with capabilities in medicinal chemistry, pharmacokinetics, toxicology, formulation development, GMP synthesis, and Phase I clinical testing. By integrating NIH resources with industry-standard expertise, BPN-SM advances investigator-initiated drug discovery while enabling investigators to retain and strengthen their intellectual property while gaining hands-on experience in translational drug development.

The overarching goal of the program is to reduce the risk of scientific and therapy development sufficiently to enable external partners to take on late-stage development and ultimately bring new therapies to patients. In addition, this BPN program is specifically focused on small molecules and excludes biologics, because development, regulatory, and manufacturing considerations for each class of therapeutics differ substantially from each other. It will use a phased cooperative agreement mechanism which will enable the program to support innovative but higher-risk projects, with decisions of continued support being contingent on demonstrated feasibility of yearly milestones. A cooperative agreement framework is proposed because several key aspects of the program will involve collaborative activities between the investigators and NIH program staff, with substantial involvement beyond the normal scope of grant stewardship. The project principal investigator(s) and NIH program staff will work jointly with NIH-supported subject matter experts to coordinate and participate in all scientific and technical management aspects of the project.

Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop competitive projects and establish the cross-disciplinary collaborations necessary for success.